The rise,fall and subsequent triumph of thalidomide: lessons learned in drug development

Abstract

Perhaps no other drug in modern medicine rivals the dramatic revitalization of thalidomide. Originally marketed as a sedative, thalidomide gained immense popularity worldwide among pregnant women because of its effective anti-emetic properties in morning sickness. Mounting evidence of human teratogenicity marked a dramatic fall from grace and led to widespread social, legal and economic ramifications. Despite its tragic past thalidomide emerged several decades later as a novel and highly effective agent in the treatment of various inflammatory and malignant diseases. In 2006 thalidomide completed its remarkable renaissance becoming the first new agent in over a decade to gain approval for the treatment of plasma cell myeloma. The catastrophic collapse yet subsequent revival of thalidomide provides important lessons in drug development. Never entirely abandoned by the medical community, thalidomide resurfaced as an important drug once the mechanisms of action were further studied and better understood. Ongoing research and development of related drugs such as lenalidomide now represent a class of irreplaceable drugs in hematological malignancies. Further, the tragedies associated with this agent stimulated the legislation which revamped the FDA regulatory process, expanded patient informed consent procedures and mandated more transparency from drug manufacturers. Finally, we review recent clinical trials summarizing selected medical indications for thalidomide with an emphasis on hematologic malignancies. Herein, we provide a historic perspective regarding the up-and-down development of thalidomide. Using PubMed databases we conducted searches using thalidomide and associated keywords highlighting pharmacology, mechanisms of action, and clinical uses.

Keywords

anti-angiogenic anti-apoptosis plasma cell myeloma teratogenic

Introduction

Historic perspective

Thalidomide was developed by the Swiss pharmaceutical company CIBA in 1953 and then was introduced by the German pharmaceutical company Chemi Grunenthal in 1956 [Rajkumar, 2004]. Initially marketed as Contergan, thalidomide was prescribed as a nonbarbiturate hypnotic sedative able to produce deep sleep without hangover or risk of dependency. Testing in rodent models failed to establish a median lethal dose and the drug was generally believed to be nontoxic to humans [Lenz, 1988]. In contrast to the extensive testing performed today, in that era formal testing for harmful teratogenic effects was not undertaken. Soon available worldwide, the drug became popular for its anti-emetic effect in pregnant woman suffering with morning sickness. Much of the drug’s popularity was due to its wide availability as it was accessible without prescription and also relatively inexpensive. In Germany it quickly became a top-selling sedative and an estimated 14.6 tons were sold in 1960 [Eriksson et al. 2001].

In 1961 Dr William McBride, an Australian obstetrician, and Dr Widukind Lenz, a German pediatrician and geneticist, made independent observations linking thalidomide use in pregnancy to congenital malformations [Lenz, 1962; McBride, 1961]. These findings were confirmed by multiple cases worldwide and thalidomide ultimately was withdrawn from the marketplace. Initial reports identified limb and bone abnormalities including amelia, phocomelia, syndactyly and underdeveloped long bones among other deformities [Lenz, 1962; Mellin and Katzenstein, 1962a, 1962b; McBride, 1961] (Figure 1). Additional observations included atresia of the esophagus, duodenum and anus as well as cardiac abnormalities and aplasia of the gallbladder and appendix [Mellin and Katzenstein, 1962b; McBride, 1961]. The majority of malformations occurred when thalidomide was ingested between 34 and 49 days after the last menstrual period, with even a single dose being associated with increased risk [Lenz, 1988]. Up to 40% of affected infants died within 1 year.

Figure 1.

(a) Single views of upper extremities in a patient exposed to thalidomide in utero. White arrow: fusion at the elbow joint and absence of fingers; Yellow arrow: absence of radius and shortening of ulna. (Reproduced with permission from LearningRadiology.com.) (b) Phocomelia in a baby.

In the United States thalidomide was briefly available as an investigational agent. The drug was endorsed as an anxiolytic but never was approved for marketing. Dr Frances Kelsey, a physician and pharmacologist, was the FDA officer assigned to review the drug application; she denied approval based on a lack of safety data. Principal in Kelsey’s decision were emerging data linking thalidomide to neurologic toxicities, including peripheral neuritis [Kelsey, 1988]. For her efforts in preventing thalidomide from being marketed and thus averting a major tragedy in the United States, Dr Kelsey was honored with the President’s Award for Distinguished Federal Civilian Service from President John F. Kennedy in 1962 (Figure 2).

Figure 2.

Dr Frances Kelsey is awarded the President’s Award for Distinguished Federal Civilian Service from President John F. Kennedy in 1962.

An estimated 10,000 infants were affected worldwide with more uncounted stillborn or miscarried pregnancies [Franks et al. 2004]. A lasting impact of these tragic events has been in the positive change in the drug regulation process. Problems with animal models and inefficiencies in the pharmaceutical agent approval process were rectified by new legislation which revamped the FDA regulatory process, expanded patient informed consent procedures and called for more transparency from drug manufacturers. As means of restitution, committees were organized in Germany to assign payment to those affected most severely. Similar organizations were formed in Britain, Canada, and Sweden. Thalidomide was withdrawn from most commercial markets by 1961 and banned worldwide by the end of the decade.

Pharmacology

Thalidomide, α-(N-phthalimido) glutarimide, is a racemic derivative of glutamic acid consisting of equal amounts of R-(+) and S-(-) enantiomers [Figg et al. 1999] (Figure 3). The enantiomers undergo rapid chiral interconversion under physiological conditions[Eriksson et al. 2001]. The (S)-isomer is an inhibitor of tumor necrosis factor (TNF)-α release from mononuclear blood cells [Wnendt et al. 1996] whereas the (R)-form correlates with sedative effects [Hoglund et al. 1998]. These differences, however, are not clinically relevant because of the rapid interconversion between enantiomers. The thalidomide molecule is subject to spontaneous hydrolysis [Schumacher et al. 1965a]. Metabolism to active metabolites appears to be responsible for the drug’s activity. Of interest, these metabolites are species specific, explaining, in part, why the actions of thalidomide are species dependant [Bauer et al. 1998; Schumacher et al. 1965b].

Figure 3.

Thalidomide interconverts between (R)- and (S)-enantiomers with protein binding of 55% and 65%, respectively. The (R)-form is responsible for sedative effects and the (S)-form is responsible for immunomodulatory effects.

No formal dose escalation studies have been conducted; however, single-dose thalidomide studies indicate that bioavailability, absorption, distribution, and elimination are dependent on dose and concurrent illness. The mean time to peak plasma concentrations range from 2.9 to 5.7 hours and peak levels are approximately 1 µg/ml. The mean half-life of elimination is approximately 5–7 hours [Teo et al. 2004; von Moos et al. 2003]. The exact metabolic route of thalidomide is not fully understood. Nonenzymatic hydrolysis leads to the formation of hydrolysis products which are primarily excreted through the urine; in total less than 1% is excreted as unchanged drug [Teo et al. 2004]. There appears to be minimal hepatic metabolism and pharmacokinetics properties in hepatic dysfunction have not been determined. No dosage modifications are needed for patients with renal dysfunction. Single clinical doses administered have ranged from 50 mg to up to 1200 mg; most clinical utility, however, appears to occur in the 50–400 mg per day range.

Mechanism of Action

The molecular mechanisms of action for the effects of thalidomide are not fully understood. Thalidomide possesses immunomodulatory, anti-inflammatory, and anti-angiogenic properties related to complex modulation of inflammatory cytokines (Figure 4). One of the primary effects of thalidomide is selective inhibition of TNF-α production in human monocytes, presumably via enhanced degradation of TNF-α mRNA [Moreira et al. 1993; Sampaio et al. 1991]. In addition, thalidomide has been shown to inhibit nuclear factor (NF)-κB activity through a process involving inhibition of I-κB kinase activity [Keifer et al. 2001]. NF-κB is a DNA binding transcription factor involved in regulating the expression of genes that contribute to the immune response, including TNF-α, interleukin (IL)-8, and IL-12 [Barnes and Karin, 1997]. Thalidomide also inhibits IL-6 and IL-12 production [Vacca et al. 2005]. Other anti-inflammatory properties include inactivation of Caspase-1, an activator of pro-inflammatory cytokines including IL-1 [Vacca et al. 2005].

Figure 4.

Proposed mechanisms of action of thalidomide upon tumorous plasma cell and surrounding microenvironment. In addition to direct inhibitory effects on the malignant plasma cell, thalidomide enhances the immune system effector cells, suppresses angiogenesis, inhibits various cytokine mediators and interferes with the bone marrow stromal cell-malignant plasma cell interaction (adhesion molecule interference, yellow circle). NK, natural killer; TNF, tumor necrosis factor; IL-6, interleukin-6; VEGF, vascular endothelial growth factor. The circular 'plus sign' indicates stimulation and the circular 'minus sign' indicates inhibition. Illustration courtesy of Alessandro Baliani © [2011].

Thalidomide potently stimulates T cells with preferential proliferation in the CD8⁺ T-cell subset [Haslett et al. 1998]. In addition, thalidomide is effective in T helper cell (Th) immunoregulation by preferentially inducing Th2 cytokine production and inhibiting Th1 cytokine production in peripheral mononuclear cells. This activity shifts the nature of T lymphocyte-dependent immune responses whereby enhancing IL-4 production and inhibiting interferon (IFN)-γ production [McHugh et al. 1995].

In 1971, Dr Judah Folkman proposed that tumors required angiogenesis for survival; hence, strategies designed to interfere with growth of new blood vessels could be effective cancer treatment [Folkman, 1971]. After this discovery, the knowledge regarding the different features of tumor vasculature compared with normal vasculature has proliferated dramatically. Identification of various signaling pathways involved in tumor angiogenesis such as Hypoxia-inducible factor-1, vascular endothelial growth factor, platelet-derived growth factor, and basic fibroblastic growth factor (bFGF) have led to the development of novel therapeutic agents [Cook and Figg, 2010; Eichholz et al. 2010]. The potent anti-angiogenic properties of thalidomide were first described using a rabbit cornea model of FGF-induced neovascularization. D’Amato and colleagues postulated that thalidomide-induced birth defects were due to inhibited blood vessel growth in the developing fetal limb bud and perhaps a similar mechanism may inhibit vasculogenesis in the tumor microenvironment [D'Amato et al. 1994]. Kenyon and colleagues described thalidomide as an inhibitor of angiogenesis in a mouse cornea model, hypothesizing that thalidomide significantly inhibits bFGF and vascular endothelial growth factor (VEGF)-induced corneal neovascularization [Kenyon et al. 1997]. They further characterized the S(-) enantiomer as responsible for the anti-angiogenic properties and identified phthaloylglutamic acid as one metabolite which retains anti-angiogenic activity in the cornea model [Kenyon et al. 1997].

Ito and coworkers proposed that the mechanism of thalidomide anti-angiogenesis, and thus its teratogenic properties, is related to direct thalidomide binding and inhibition of cereblon which is a component of an E3 ubiquitin ligase complex [Ito et al. 2010]. The ligase activity is important in the expression of FGF and therefore implicated in angiogenesis regulation, cell signaling and limb outgrowth [Toffalini and Demoulin, 2010; Hideshima et al. 2000]. In addition to anti-angiogenic properties, thalidomide has several actions against plasma cell myeloma. Thalidomide inhibits tumor cell adhesion and cell–cell communication important for proliferation and survival. Cytokines important for plasma cell growth in the bone marrow microenvironment include IL-6, IL-10, and TNF-α which are inhibited by thalidomide. Lastly, thalidomide may directly prevent myeloma cell growth by inducing free radical-mediated DNA damage [Segarra et al. 2010; Mitsiades et al. 2002; Hideshima et al. 2000]. These varied properties have justified use of this agent for antimyeloma therapy.

Toxicity

In addition to the well-known teratogenicity, adverse effects of thalidomide include peripheral neuropathies and sedation occurring in up to 30% and 50% of patients, respectively [Chaudhry et al. 2008, 2002]. Using electrophysiologic studies, thalidomide-associated neuropathies tend to manifest as axonal sensory injuries more so than motor. Polyneuropathies often present as painful paresthesias or numbness; such correlate with total cumulative exposure to thalidomide [Chaudhry et al. 2008]. Johnson and colleagues reported the identification of a series of single nucleotide polymorphisms (SNPs) which were associated with thalidomide-related neuropathy. These findings suggest that genetic factors may mediate the risk for developing neuropathies [Johnson et al. 2011].

Another serious reported complication is toxic epidermal necrolysis occurring in 3–4% of patients [Colagrande et al. 2009; Rajkumar et al. 2000]. Other more common but less severe toxicities include rash, constipation, tremor, and interstitial pneumonia. Metabolic abnormalities include hypothyroidism, hypocalcemia, and hyperkalemia, particularly in myeloma patients with pre-existing kidney dysfunction [Pretz and Medeiros, 2009; de Savary et al. 2004; Fakhouri et al. 2004; Ghobrial and Rajkumar, 2003; Harris et al. 2003; Badros et al. 2002] (see Table 1 for reported incidence of adverse events).

Table 1.

Selected adverse events occurring in ≥10% of patients as listed in the thalidomide package insert; 30% of patients in thalidomide containing arm discontinued drug due to adverse events.

Adverse event
Constipation	All events 55%	Grade 3–4 8%
Neuropathy: sensory	54%	4%
Neuropathy: motor	22%	8%
Tremor	26%	1%
Fatigue	79%	17%
Edema	57%	6%
Thrombosis	23%	22%
Rash/desquamation	30%	4%
Leukopenia	35%	7%
Thrombocytopenia	24%	4%

Thrombotic complications

Plasma cell myeloma is associated with increased thrombotic events. Proposed mechanisms are coagulation factor abnormalities including higher concentrations of von Willebrand factor and factor VIII, activated protein C resistance, and hypofibrinolysis [Auwerda et al. 2007; Elice et al. 2006; van Marion et al. 2005; Zangari et al. 2002a]. Thalidomide, particularly as part of combination therapy in plasma cell myeloma, further increases risk for thrombotic events [Carrier et al. 2011; Zangari et al. 2009]. This hazard is further increased with the addition of more traditional cytotoxic agents, particularly anthracycline chemotherapy [Zangari et al. 2002b, 2001]. Both venous and arterial thrombotic events have been described [Libourel et al. 2010; Martin and Vij, 2009; Scarpace et al. 2005]. While thalidomide monotherapy minimally increases the likelihood of thrombosis, in large randomized trials evaluating thalidomide plus dexamethasone the reported rate of deep venous thrombosis is increased to 17–19% [Rajkumar et al. 2008, 2006].

A suggested mechanism by which thalidomide may promote thrombosis is modification of thrombomodulin levels in the first month of therapy [Corso et al. 2004]. Thrombomodulin complexes with thrombin in the anticoagulant interactions with protein C; the transient decrease in thrombomodulin plasma concentration may promote a thrombophilic state. In addition, thalidomide-derived immunomodulatory drugs downregulate PU.1 which is a transcription factor involved in granulocyte differentiation. This action leads to promyelocyte accumulation and resultant high levels of cathepsin G, a platelet aggregation agonist stored in promyelocyte granules, which may increase the risk for thrombotic events [Pal et al. 2010].

Coagulation prevention strategies include use of aspirin, low or therapeutic doses of warfarin, and low molecular weight heparin (LMWH). An Italian randomized, phase III trial evaluated prophylactic use of aspirin (100 mg/day), warfarin (1.25 mg/day), or LMWH (40 mg/day) in previously untreated plasma cell myeloma patients who received regimens containing thalidomide. Serious thrombotic event rates in the aspirin, warfarin, and LMWH group were 6.4%, 8.2%, and 5%, respectively [Palumbo et al. 2011].

Thalidomide revival

Despite being banned from commercial markets, thalidomide remained available primarily in developing countries. Clinical interest in thalidomide resurfaced after Dr Jacob Sheskin first prescribed thalidomide in 1964 as a sedative in a patient with erythema nodosum leprosum (ENL). Sheskin was at the Hadassah University Hospital and Hansen Leper Hospital in Jerusalem. He observed an unexpected and dramatic resolution of the patient’s lepra skin eruption within 48 hours of administration. This activity later was reproduced and reported by Sheskin in 1965 [Sheskin, 1965a, 1965b]. In 1971 the World Health Organization published the results of a randomized trial that confirmed the efficacy of thalidomide in ENL [Silverman, 2002; Iyer et al. 1971].

After the reported success in treating ENL, thalidomide was supported on an experimental basis by the FDA in the 1970s primarily in other dermatologic and inflammatory conditions. The drug also became available through various compassionate use programs for its sedative properties. Thalidomide use was subsequently researched in a number of inflammatory conditions including sarcoidosis, cutaneous lupus, Behçet’s syndrome, inflammatory bowel diseases, ankylosing spondylitis, and rheumatoid arthritis [Lazzerini et al. 2007; Lehman et al. 2004; Wei et al. 2003; Bauditz et al. 2002; Vasiliauskas et al. 1999; Hamuryudan et al. 1998].

Thalidomide also was evaluated in refractory or high-risk chronic graft-versus- host disease (GVHD). Using escalating doses ranging from 200–1600 mg per day, response rates varied from 20% to 79% [Arora et al. 2001; Parker et al. 1995; Vogelsang et al. 1992]. In one trial in which 59 subjects were randomized to receive either thalidomide or placebo as GVHD prophylaxis, however, the thalidomide group was associated with higher incidence of GVHD and worse survival [Chao et al. 1996]. While thalidomide has been shown to be an effective agent for the therapy of chronic GVHD, prophylactic use resulted in a paradoxical outcome with a higher incidence of chronic GVHD and a lower overall survival. The authors concluded that early thalidomide use resulted in a shift in the balance between GVHD and induction of tolerance.

A novel application of thalidomide’s anti-emetic, sedative, and analgesic properties has been in the palliative care setting, particularly cancer cachexia and HIV wasting syndrome [von Moos et al. 2003; Peuckmann et al. 2000]. Furthering the clinical revival of this agent, thalidomide emerged as an effective drug to treat complications of HIV disease such as the HIV wasting syndrome, Kaposi’s sarcoma, and aphthous ulcers [Little et al. 2000; Jacobson et al. 1997; Reyes-Teran et al. 1996].

These findings led to continued thalidomide availability in controlled clinical trials and on a compassionate use basis. By this time ‘drug buyer’ clubs were being established in major cities. These groups were channeling sometimes impure forms of thalidomide through the growing black market in South America, most notably Brazil, where thalidomide had remained largely available since its inception. The primarily unregulated distribution of thalidomide pressed the FDA into soliciting drug applications from several companies that were investigating the drug. Celgene Corporation gained approval to formally market the drug. In 1998 the FDA approved thalidomide for the treatment of ENL, an action that facilitated the continued availability of the drug for other conditions [Rajkumar, 2004] (Figure 5).

Figure 5.

Timeline of events in thalidomide and immunomodulatory drug (IMiD) development.

Anticancer properties

The potential benefit of thalidomide in cancer treatment first was hypothesized in the 1960s shortly after the teratogenic properties were reported. Investigators believed that the effects responsible for teratogenicity also represented potential mechanisms for cancer treatment. For a variety of reasons, the early clinical trials exploring thalidomide as an antitumor agent, however, failed to show significant activity [Rajkumar and Kyle, 2001; Grabstald and Golbey, 1965; Olson et al. 1965]. More recently, promising results have been noted in castrate-resistant prostate cancer. A phase II trial of 60 patients using thalidomide as an alternative anti-angiogenic agent added to standard chemotherapy and bevacizumab demonstrated a prostate-specific antigen (PSA) decline of at least 50% in 90% of patients [Ning et al. 2010]. Mixed results have been reported in other solid tumors where angiogenesis is implicated including renal cell, hepatocellular, and ovarian cancers [Ch'ang et al. 2011; Hurteau et al. 2010; Motzer et al. 2002]. Currently multiple phase II and phase III trials are exploring thalidomide as an adjunctive agent in various solid tumors.

To minimize the risk of teratogenicity, thalidomide access is restricted through the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) program. All prescribing physicians, pharmacies, and patients must register with the program and comply with safety guidelines in order to control the prescribing, dispensing, and use of thalidomide [Zeldis et al. 1999]. In addition to minimizing the potential risk for fetal harm associated with thalidomide therapy, this strategy provided a model for future cases in which drug therapy offers compelling benefits but poses profound risks unless its distribution is carefully controlled.

Hematologic malignancies

Plasma cell myeloma

The discovery of potent anti-angiogenic properties renewed interest in the use of thalidomide as an antitumor agent. Plasma cell myeloma is associated with increased bone marrow microvascular density and elevated serum VEGF concentration. These features led to the recognition that angiogenesis is an important pathogenic mechanism in this disorder and prompted clinical use [Kotla et al. 2009]. The investigators at the University of Arkansas first reported a 32% overall response rate with single-agent thalidomide in a series of 84 refractory plasma cell myeloma patients [Singhal et al. 1999]. A follow-up study of escalated doses resulted in a reported overall survival of 48% at 2 years [Barlogie et al. 2001]. Updated results at a median follow up of 9.2 years suggested better overall survival in patients receiving higher cumulative doses of thalidomide, suggesting a dose-dependent effect [van Rhee et al. 2008]. Additional prospective studies using single-agent thalidomide further confirmed the benefit of thalidomide monotherapy [van Rhee et al. 2008; Richardson et al. 2004; Kumar et al. 2003; Mileshkin et al. 2003]. Systematic reviews of phase II trial data demonstrate response rates of 30% with overall median survival of 14 months in refractory disease patients treated with thalidomide monotherapy [Prince et al. 2007; Glasmacher et al. 2006]. Subsequently, the thalidomide and dexamethasone combination therapy was found to enhance response rates [Rajkumar, 2011; Murakami et al. 2007; Anagnostopoulos et al. 2003]. A literature review by von Lilienfeld-Toal and colleagues of 12 studies in 451 patients of the thalidomide and dexamethasone combination therapy demonstrated an increased overall response rate of 46% in relapsed/refractory plasma cell myeloma patients, but with a toxicity rate comparable to thalidomide monotherapy [von Lilienfeld-Toal et al. 2008].

Thalidomide combination therapy for newly diagnosed plasma cell myeloma has resulted in an improved overall response rate as well as a lengthening of time to disease progression; such combinations have become the standard [Hussein et al. 2009; Weber et al. 2003; Rajkumar et al. 2002]. Complete response rates and 5-year event-free survival rates of 62% and 56%, respectively, were noted in a study incorporating thalidomide into high-dose therapy and autologous hematopoietic cell transplant [Barlogie et al. 2006]. Two randomized controlled trials have compared the thalidomide plus dexamethasone combination versus dexamethasone alone as induction therapy in newly diagnosed untreated patients. Combination treatment resulted in significantly better overall response rates of 63% and extended time to progression from 6.5 to 22.6 months [Rajkumar et al. 2008, 2006] (Table 2).

Table 2.

Outcomes in selected plasma cell myeloma trials.

Patient type and numbers	Daily dose	Overall response rate
Refractory myeloma
Thalidomide monotherapy
84	200–800 mg	32%
32	200–800 mg	31%
169	200–800 mg	37%
30	200–600 mg	43%
Thalidomide
± IFN-α
75	200–800 mg	25%
Thalidomide
± Dexamethasone
66*	100–200 mg + dexamethasone	64%
47*	200–800 mg + dexamethasone	47%
Untreated myeloma
Thalidomide combination
103*	200 mg + dexamethasone	63%
235*	50–200 mg + dexamethasone	63%
113*	200 mg + melphalan/prednisone	66%
129*	100 mg + melphalan/prednisone	76%
182*	200–400 mg + melphalan/prednisone	57%
165	200 mg + melphalan/prednisone	66%
130	100 mg + bortezomib/prednisone	81%

Only the thalidomide arm of the trial is listed.

IFN, interferon.

Table 3.

Immunomodulatory drugs (IMiDs) comparative activity.

Property	Thalidomide	Lenalidomide	Pomalidomide
Anti-inflammation	+	+ + + +	+ + + + +
T cell co-stimulation	+	+ + + +	+ + + + +
Anti-angiogenesis	+ + + +	+ + +	+ + + +
Anti-proliferation	+	+ + +	+ + + +
Pro-erythrogenesis	+	+ +	+ + + +

The addition of bortezomib to thalidomide and dexamethasone induction treatment also improves complete response rates. In a phase III trial evaluating 474 patients bortezomib, thalidomide and dexamethasone (VTD) induction therapy yielded a complete or near complete response rate of 31% [Cavo et al. 2010]. Similarly, bortezomib, thalidomide, and prednisone use provided a median progression-free survival of 25 months and 65% overall 3-year survival [Mateos et al. 2010].

Among elderly patients or those who are not candidates for hematopoietic cell transplantation, thalidomide in combination with melphalan and prednisone significantly improves event-free and overall survival. Median progression-free survival rates range from 15 to 28 months and overall survival ranges from 40 to 52 months [Kapoor et al. 2011; Waage et al. 2010; Wijermans et al. 2010; Hulin et al. 2009; Facon et al. 2007]. These patients typically were over 65–75 years of age.

Recent studies have evaluated the role for thalidomide maintenance therapy but the data have shown conflicting results as the clinical benefit is unclear yet the toxic effects generally are increased. One study evaluated thalidomide combined with dexamethasone maintenance. The two year progression-free survival improved from 32% to 63% and 2-year overall survival improved from 68% to 84% [Offidani et al. 2009]. In another study, however, thalidomide plus IFN maintenance therapy improved progression-free survival from 13.2 to 27.7 months but without a significant difference in overall survival [Ludwig et al. 2010].

Thalidomide maintenance treatment also has been studied in the post-transplant setting. One trial randomized 556 patients to receive vincristine, doxorubicin and dexamethasone induction (VAD) followed by interferon maintenance versus thalidomide, doxorubicin, and dexamethasone induction (TAD) followed by thalidomide posttransplant. The thalidomide group had an improved progression-free survival from 25 to 34 months; however, there was no statistically significant difference in overall survival [Lokhorst et al. 2010]. A second trial assigned 269 patients to receive thalidomide plus prednisolone, versus prednisolone alone, after autologous transplant. At 3-year follow up, patients assigned to the thalidomide group had improved progression-free survival (42% versus 23%) and overall survival (86% versus 75%) [Spencer et al. 2009]. Thalidomide was continued for 12 months duration and therefore can be considered as consolidation as opposed to maintenance effect. Neurologic toxicities led to discontinuation of thalidomide in up to 60% of patients. Hence, it is unclear which population benefits the most from maintenance therapy.

Thalidomide therapy also has been evaluated in combination with conventional chemotherapeutic agents including anthracyclines and alkylators such as cyclophosphamide. Despite reports of higher response rates in some studies, however, the lack of convincing survival benefit along with higher toxic effects including thrombotic and infectious complications make these regimens less attractive [Ciolli et al. 2008; Offidani et al. 2007; Kyriakou et al. 2005]. In May of 2006, thalidomide was approved for the treatment of newly diagnosed plasma cell myeloma in combination with dexamethasone.

Myelofibrosis

Thalidomide has been used as an effective agent in the treatment of myelofibrosis. Preliminary data suggest improvement in cytopenias and splenomegaly. In a study of 36 patients with median follow-up of 25 months, 28% of patients had a durable response to thalidomide [Thomas et al. 2006; Marchetti et al. 2004; Mesa et al. 2004].

Myelodysplastic syndromes

Based on anticytokine immunomodulatory and anti-angiogenic properties, thalidomide has been used in the treatment of myelodysplastic syndromes. Erythroid response in transfusion-dependent patients has been good; however, patients poorly tolerate effective (higher) doses. Thalidomide doses used in clinical trials were in the range 200–1000 mg per day. Such dosing variability may explain the inconsistent study results as well as the various toxicities in this setting [Moreno-Aspitia et al. 2006; Bouscary et al. 2005; Musto, 2004].

Waldenstrom macroglobulinemia

Phase II studies have shown excellent activity of thalidomide alone or in combination with other agents as therapy in Waldenstrom macroglobulinemia [Dimopoulos et al. 2009; Dimopoulos et al. 2001]. Treon and coworkers reported a 72% overall response rate in primarily untreated patients using thalidomide and rituximab for symptomatic disease [Treon et al. 2008]. Median serum IgM significantly decreased from 3670 to 1590 mg/dl and median hematocrit rose from 33.0% to 37.6% (p = 0.004) at time of best response; for responders, median time to progression was 38 months. Thalidomide antitumor activity has been modest in non-Hodgkin lymphoma, acute myeloid leukemia, and chronic lymphocytic leukemia [Kay et al. 2009; Smith et al. 2008; Barr et al. 2007; Laurenti et al. 2007].

Alternative uses

The vascular effects of thalidomide have led to further innovative uses. Thalidomide has been used successfully to control recurrent, obscure gastrointestinal bleeding or refractory bleeding from angiodysplasia [Almadi et al. 2009; Szilagyi and Ghali, 2006; Bauditz et al. 2004]. These results have extended to patients with von Willebrand’s disease [Nomikou et al. 2009]. Lebrin and colleagues reported the successful use of thalidomide therapy to reduce the frequency of epistaxis in a group of hereditary hemorrhagic telangiectasia (HHT) patients [Lebrin et al. 2010]. They postulated that thalidomide bypasses an endothelial cell regulatory pathway, thereby stimulating vessel maturation and preventing vessel wall malformations [Akhurst, 2010; Lebrin et al. 2010].

Immunomodulatory derivatives

Thalidomide analogues, termed immunomodulatory drugs (IMiDs), are a class of agents developed to take advantage of the anti-inflammatory and antitumor properties of thalidomide while maintaining a more favorable side effect profile (Table 3). Lenalidomide (Revlimid, CC-5013) and pomalidomide (CC-4047) are two such analogues [Begna et al. 2011; Lacy et al. 2010]. Lenalidomide is approved as an effective treatment in relapsed plasma cell myeloma and myelodysplastic syndromes associated with the deletion 5q abnormality [Rajkumar et al. 2010; List et al. 2006]. Two randomized clinical trials compared lenalidomide (initial dose 25 mg per day) plus dexamethasone versus dexamethasone therapy alone in myeloma patients who had received at least one prior treatment. Both studies showed improvement in the primary endpoint of time to progression [Dimopoulos et al. 2007; Weber et al. 2007]. Lenalidomide also was evaluated in a study of 148 patients with transfusion-dependant anemia in intermediate-1 risk myelodysplastic syndrome and deletion 5q abnormality. Lenalidomide was shown to decrease transfusion requirements as 67% of patients achieved transfusion independence. A daily 10 mg dose was used and median time to response was 4.6 weeks [List et al. 2006].

Pomalidomide is a potent investigational thalidomide analogue. Encouraging early phase clinical trials have shown activity in relapsed plasma cell myeloma and myelofibrosis. Typical doses range from 2 to 5 mg per day and generally are well-tolerated [Lacy and Rajkumar, 2010].

Myelosuppression is the dose-limiting toxicity for both lenalidomide and pomalidomide. Peripheral neuropathies are generally less severe as compared with thalidomide. The incidence of venous thromboembolism is approximately 7–8% [Dimopoulos et al. 2007; Weber et al. 2007]. Both lenalidomide and pomalidomide are listed as Category X drugs in pregnancy. Other adverse toxicities include rash, constipation, and fatigue [Richardson and Anderson, 2002]. Ongoing development and research of thalidomide analogues, in addition to further identification of thalidomide metabolites and their actions, should lead to promising new treatments in hematologic malignancies.

Conclusions

It is highly likely that no one could have predicted such a clinical resurgence for thalidomide nearly four decades after the recognition of teratogenicity. The thalidomide saga is directly responsible for many changes in the drug development proceedings by highlighting many of the shortfalls in this approval process. In the United States new laws were passed that implemented strict regulations, restructured the FDA, and protected patients and consumers by expanding the informed consent process. At present, manufacturers must prove both effectiveness and safety of a new agent before it is authorized to be tested on humans. Another result was that all drugs must undergo formal testing for teratogenic effects; as a result, the teratology field has developed rapidly.

Beyond the social and legal implications, other lessons have been learned from the scientific advancements made after Dr Sheskin first used thalidomide in ENL. As the complex mechanisms of action and associated toxicities were better understood, thalidomide was applied to a variety of disorders. This previously ill-fated, teratogenic sedative possessed unusual anti-inflammatory and anti-angiogenic properties. Gaining insight into these mechanisms allowed clinicians to utilize thalidomide as an antitumor agent. Under the careful supervision of the S.T.E.P.S. program, continued research and development of thalidomide analogues represent additional potential for new treatments. The new legacy for thalidomide will be judged by these significant advancements. From past tragedies to present triumphs, we now look to a future full of immeasurable promise.

Footnotes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

Professor Lazarus has been a speaker for Celgene Corporation.

References

Akhurst

R.J.

(2010) Taking thalidomide out of rehab. Nat Med 16: 370–372.

Almadi

Ghali

P.M.

Constantin

Galipeau

Szilagyi

(2009) Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies Case series and review. Can J Gastroenterol 23: 625–631.

Anagnostopoulos

Weber

Rankin

Delasalle

Alexanian

(2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121: 768–771.

Arora

Wagner

J.E.

Davies

S.M.

Blazar

B.R.

Defor

Enright

(2001) Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 7: 265–273.

Auwerda

J.J.

Sonneveld

de Maat

M.P.

Leebeek

F.W.

(2007) Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 92: 279–280.

Badros

A.Z.

Siegel

Bodenner

Zangari

Zeldis

Barlogie

(2002) Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 112: 412–413.

Barlogie

Desikan

Eddlemon

Spencer

Zeldis

Munshi

(2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98: 492–494.

Barlogie

Tricot

Anaissie

Shaughnessy

Rasmussen

van Rhee

(2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021–1030.

Barnes

P.J.

Karin

(1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066–1071.

10.

Barr

Lazarus

Kane

Meyerson

Hartman

(2007) Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leuk Lymphoma 48: 1940–1949.

11.

Bauditz

Schachschal

Wedel

Lochs

(2004) Thalidomide for treatment of severe intestinal bleeding. Gut 53: 609–612.

12.

Bauditz

Wedel

Lochs

(2002) Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196–200.

13.

Bauer

K.S.

Dixon

S.C.

Figg

W.D.

(1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827–1834.

14.

Begna

K.H.

Mesa

R.A.

Pardanani

Hogan

W.J.

Litzow

M.R.

McClure

R.F.

(2011) A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25: 301–304.

15.

Bouscary

Legros

Tulliez

Dubois

Mahe

Beyne-Rauzy

(2005) A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol 131: 609–618.

16.

Carrier

M.G.L.E.G.

Tay

Lee

A.Y.

(2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9: 653–663.

17.

Cavo

Tacchetti

Patriarca

Petrucci

M.T.

Pantani

Galli

(2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376: 2075–2085.

18.

Ch'ang

H.J.

Hsu

Chen

C.H.

Chang

Y.H.

Chang

J.S.

Chen

L.T.

(2011) Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys in press.

19.

Chao

N.J.

Parker

P.M.

Niland

J.C.

Wong

R.M.

Dagis

Long

G.D.

(1996) Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 2: 86–92.

20.

Chaudhry

Cornblath

D.R.

Corse

Freimer

Simmons-O'Brien

Vogelsang

(2002) Thalidomide-induced neuropathy. Neurology 59: 1872–1875.

21.

Chaudhry

Cornblath

D.R.

Polydefkis

Ferguson

Borrello

(2008) Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 13: 275–282.

22.

Ciolli

Leoni

Casini

Breschi

Santini

Bosi

(2008) The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 141: 814–819.

23.

Colagrande

Di Ianni

Coletti

Peris

Fargnoli

M.C.

Moretti

(2009) Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. Int J Hematol 89: 76–79.

24.

Cook

K.M.

Figg

W.D.

(2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60: 222–243.

25.

Corso

Lorenzi

Terulla

Airo

Varettoni

Mangiacavalli

(2004) Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 83: 588–591.

26.

D'Amato

R.J.

Loughnan

M.S.

Flynn

Folkman

(1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91: 4082–4085.

27.

de Savary

Lee

Vaidya

(2004) Severe hypothyroidism after thalidomide treatment. J R Soc Med 97: 443–443.

28.

Dimopoulos

Spencer

Attal

Prince

H.M.

Harousseau

J.L.

Dmoszynska

(2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123–2132.

29.

Dimopoulos

M.A.

Gertz

M.A.

Kastritis

Garcia-Sanz

Kimby

E.K.

Leblond

(2009) Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 27: 120–126.

30.

Dimopoulos

M.A.

Zomas

Viniou

N.A.

Grigoraki

Galani

Matsouka

(2001) Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 19: 3596–3601.

31.

Eichholz

Merchant

Gaya

A.M.

(2010) Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 3: 69–82.

32.

Elice

Fink

Tricot

Barlogie

Zangari

(2006) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134: 399–405.

33.

Eriksson

Bjorkman

Hoglund

(2001) Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57: 365–376.

34.

Facon

Mary

J.Y.

Hulin

Benboubker

Attal

Pegourie

(2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370: 1209–1218.

35.

Fakhouri

Guerraoui

Presne

Peltier

Delarue

Muret

(2004) Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 125: 96–97.

36.

Figg

W.D.

Raje

Bauer

K.S.

Tompkins

Venzon

Bergan

(1999) Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 88: 121–125.

37.

Folkman

(1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186.

38.

Franks

M.E.

Macpherson

G.R.

Figg

W.D.

(2004) Thalidomide. Lancet 363: 1802–1811.

39.

Ghobrial

I.M.

Rajkumar

S.V.

(2003) Management of thalidomide toxicity. J Support Oncol 1: 194–205.

40.

Glasmacher

Hahn

Hoffmann

Naumann

Goldschmidt

von Lilienfeld-Toal

(2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132: 584–593.

41.

Grabstald

Golbey

(1965) Clinical experiences with thalidomide in patients with cancer. Clin Pharmacol Ther 6: 298–302.

42.

Hamuryudan

Mat

Saip

Ozyazgan

Siva

Yurdakul

(1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128: 443–450.

43.

Harris

Behrens

Samson

Rahemtulla

Russell

N.H.

Byrne

J.L.

(2003) Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 122: 160–161.

44.

Haslett

P.A.

Corral

L.G.

Albert

Kaplan

(1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187: 1885–1892.

45.

Hideshima

Chauhan

Shima

Raje

Davies

F.E.

Tai

Y.T.

(2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943–2950.

46.

Hoglund

Eriksson

Bjorkman

(1998) A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet Biopharm 26: 363–383.

47.

Hulin

Facon

Rodon

Pegourie

Benboubker

Doyen

(2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27: 3664–3670.

48.

Hurteau

J.A.

Brady

M.F.

Darcy

K.M.

McGuire

W.P.

Edmonds

Pearl

M.L.

(2010) Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol 119: 444–450.

49.

Hussein

M.A.

Bolejack

Zonder

J.A.

Durie

B.G.

Jakubowiak

A.J.

Crowley

J.J.

(2009) Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol 27: 3510–3517.

50.

Ito

Ando

Suzuki

Ogura

Hotta

Imamura

(2010) Identification of a primary target of thalidomide teratogenicity. Science 327: 1345–1350.

51.

Iyer

C.G.

Languillon

Ramanujam

Tarabini-Castellani

De las Aguas

J.T.

Bechelli

L.M.

(1971) WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 45: 719–732.

52.

Jacobson

J.M.

Greenspan

J.S.

Spritzler

Ketter

Fahey

J.L.

Jackson

J.B.

(1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336: 1487–1493.

53.

Johnson

D.C.

Corthals

S.L.

Walker

B.A.

Ross

F.M.

Gregory

W.M.

Dickens

N.J.

(2011) Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29: 797–804.

54.

Kapoor

Rajkumar

S.V.

Dispenzieri

Gertz

M.A.

Lacy

M.Q.

Dingli

(2011) Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 25: 689–696.

55.

Kay

N.E.

Shanafelt

T.D.

Call

T.G.

Laplant

B.R.

(2009) N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma 50: 588–592.

56.

Keifer

J.A.

Guttridge

D.C.

Ashburner

B.P.

Baldwin

A.S.

Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276: 22382–22387.

57.

Kelsey

F.O.

(1988) Thalidomide update: regulatory aspects. Teratology 38: 221–226.

58.

Kenyon

B.M.

Browne

D'Amato

R.J.

(1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64: 971–978.

59.

Kotla

Goel

Nischal

Heuck

Vivek

Das

(2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2: 36–36.

60.

Kumar

Gertz

M.A.

Dispenzieri

Lacy

M.Q.

Geyer

S.M.

Iturria

N.L.

(2003) Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78: 34–39.

61.

Kyriakou

Thomson

D'Sa

Flory

Hanslip

Goldstone

A.H.

(2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 129: 763–770.

62.

Lacy

M.Q.

Hayman

S.R.

Gertz

M.A.

Short

K.D.

Dispenzieri

Kumar

(2010) Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24: 1934–1939.

63.

Lacy

M.Q.

Rajkumar

S.V.

(2010) Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. Am J Hematol 85: 95–96.

64.

Laurenti

Piccioni

Tarnani

De Padua

Garzia

Efremov

D.G.

(2007) Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res 31: 253–256.

65.

Lazzerini

Martelossi

Marchetti

Scabar

Bradaschia

Ronfani

(2007) Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 25: 419–427.

66.

Lebrin

Srun

Raymond

Martin

van den Brink

Freitas

(2010) Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16: 420–428.

67.

Lehman

T.J.

Schechter

S.J.

Sundel

R.P.

Oliveira

S.K.

Huttenlocher

Onel

K.B.

(2004) Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr 145: 856–857.

68.

Lenz

(1962) Thalidomide and congenital abnormalities. Lancet 1: 45–45.

69.

Lenz

(1988) A short history of thalidomide embryopathy. Teratology 38: 203–215.

70.

Libourel

E.J.

Sonneveld

van der Holt

de Maat

M.P.

Leebeek

F.W.

(2010) High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 116: 22–26.

71.

List

Dewald

Bennett

Giagounidis

Raza

Feldman

(2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355: 1456–1465.

72.

Little

R.F.

Wyvill

K.M.

Pluda

J.M.

Welles

Marshall

Figg

W.D.

(2000) Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18: 2593–2602.

73.

Lokhorst

H.M.

van der Holt

Zweegman

Vellenga

Croockewit

van Oers

M.H.

(2010) A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115: 1113–1120.

74.

Ludwig

Adam

Tothova

Hajek

Labar

Egyed

(2010) Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 95: 1548–1554.

75.

Marchetti

Barosi

Balestri

Viarengo

Gentili

Barulli

(2004) Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 22: 424–431.

76.

Martin

M.G.

Vij

(2009) Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature. Clin Lymphoma Myeloma 9: 320–323.

77.

Mateos

M.V.

Oriol

Martinez-Lopez

Gutierrez

Teruel

A.I.

de Paz

(2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11: 934–941.

78.

McBride

W.G.

(1961) Thalidomide and congenital abnormalities. Lancet 2: 1358–1358.

79.

McHugh

S.M.

Rifkin

I.R.

Deighton

Wilson

A.B.

Lachmann

P.J.

Lockwood

C.M.

(1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99: 160–167.

80.

Mellin

G.W.

Katzenstein

(1962a) The saga of thalidomide Neuropathy to embryopathy, with case reports of congenital anomalies (continued). N Engl J Med 267: 1184–1192.

81.

Mellin

G.W.

Katzenstein

(1962b) The saga of thalidomide Neuropathy to embryopathy, with case reports of congenital anomalies (conclusion). N Engl J Med 267: 1238–1244.

82.

Mesa

R.A.

Elliott

M.A.

Schroeder

Tefferi

(2004) Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 79: 883–889.

83.

Mileshkin

Biagi

J.J.

Mitchell

Underhill

Grigg

Bell

(2003) Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102: 69–77.

84.

Mitsiades

C.S.

Poulaki

Chauhan

Richardson

P.G.

Hideshima

(2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99: 4525–4530.

85.

Moreira

A.L.

Sampaio

E.P.

Zmuidzinas

Frindt

Smith

K.A.

Kaplan

(1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675–1680.

86.

Moreno-Aspitia

Colon-Otero

Hoering

Tefferi

Niedringhaus

R.D.

Vukov

(2006) Thalidomide therapy in adult patients with myelodysplastic syndrome A North Central Cancer Treatment Group phase II trial. Cancer 107: 767–772.

87.

Motzer

R.J.

Berg

Ginsberg

Russo

Vuky

(2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20: 302–306.

88.

Murakami

Handa

Abe

Iida

Ishii

Ishikawa

(2007) Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 79: 234–239.

89.

Musto

(2004) Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28: 325–332.

90.

Ning

Y.M.

Gulley

J.L.

Arlen

P.M.

Woo

Steinberg

S.M.

Wright

J.J.

(2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 2070–2076.

91.

Nomikou

Tsevrenis

Gafou

Bellia

Theodossiades

(2009) Type IIb von Willebrand disease with angiodysplasias and refractory gastrointestinal bleeding successfully treated with thalidomide. Haemophilia 15: 1340–1342.

92.

Offidani

Bringhen

Corvatta

Falco

Marconi

Avonto

(2007) Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol 78: 297–302.

93.

Offidani

Corvatta

Polloni

Piersantelli

M.N.

Gentili

Galieni

(2009) Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br J Haematol 144: 653–659.

94.

Olson

K.B.

Hall

T.C.

Horton

Khung

C.L.

Hosley

H.F.

(1965) Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 6: 292–297.

95.

Pal

Monaghan

S.A.

Hassett

A.C.

Mapara

M.Y.

Schafer

Roodman

G.D.

(2010) Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 115: 605–614.

96.

Palumbo

Cavo

Bringhen

Zamagni

Romano

Patriarca

(2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29: 986–993.

97.

Parker

P.M.

Chao

Nademanee

O'Donnell

M.R.

Schmidt

G.M.

Snyder

D.S.

(1995) Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 86: 3604–3609.

98.

Peuckmann

Fisch

Bruera

(2000) Potential novel uses of thalidomide: focus on palliative care. Drugs 60: 273–292.

99.

Pretz

Medeiros

B.C.

(2009) Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. Am J Hematol 84: 698–699.

100.

Prince

H.M.

Schenkel

Mileshkin

(2007) An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 48: 46–55.

101.

Rajkumar

S.V.

(2004) Thalidomide: tragic past and promising future. Mayo Clin Proc 79: 899–903.

102.

Rajkumar

S.V.

(2011) Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86: 57–65.

103.

Rajkumar

S.V.

Blood

Vesole

Fonseca

Greipp

P.R.

(2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24: 431–436.

104.

Rajkumar

S.V.

Gertz

M.A.

Witzig

T.E.

(2000) Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343: 972–973.

105.

Rajkumar

S.V.

Hayman

Gertz

M.A.

Dispenzieri

Lacy

M.Q.

Greipp

P.R.

(2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20: 4319–4323.

106.

Rajkumar

S.V.

Jacobus

Callander

N.S.

Fonseca

Vesole

D.H.

Williams

M.E.

(2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11: 29–37.

107.

Rajkumar

S.V.

Kyle

R.A.

(2001) Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol 19: 3593–3595.

108.

Rajkumar

S.V.

Rosinol

Hussein

Catalano

Jedrzejczak

Lucy

(2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26: 2171–2177.

109.

Reyes-Teran

Sierra-Madero

J.G.

Martinez del Cerro

Arroyo-Figueroa

Pasquetti

Calva

J.J.

(1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10: 1501–1507.

110.

Richardson

Anderson

(2002) Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 22: 3212–3214.

111.

Richardson

Schlossman

Jagannath

Alsina

Desikan

Blood

(2004) Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79: 875–882.

112.

Sampaio

E.P.

Moreira

A.L.

Kaplan

Alvim

M.F.

Duppre

N.C.

Miranda

C.F.

(1991) Mycobacterium leprae-induced interferon-gamma production by household contacts of leprosy patients: association with the development of active disease. J Infect Dis 164: 990–993.

113.

Scarpace

S.L.

Hahn

Roy

Brown

Paplham

Chanan-Khan

(2005) Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 46: 239–242.

114.

Schumacher

Smith

R.L.

Williams

R.T.

(1965a) The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol Chemother 25: 338–351.

115.

Schumacher

Smith

R.L.

Williams

R.T.

(1965b) The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol Chemother 25: 324–337.

116.

Segarra

Lozano

Corbera-Bellalta

Vilardell

Cibeira

M.T.

Esparza

(2010) Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica 95: 456–463.

117.

Sheskin

(1965a) Further observation with thalidomide in lepra reactions. Lepr Rev 36: 183–187.

118.

Sheskin

(1965b) Thalidomide in the Treatment of Lepra Reactions. Clin Pharmacol Ther 6: 303–306.

119.

Silverman

W.A.

(2002) The schizophrenic career of a "monster drug". Pediatrics 110: 404–406.

120.

Singhal

Mehta

Desikan

Ayers

Roberson

Eddlemon

(1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565–1571.

121.

Smith

S.M.

Grinblatt

Johnson

J.L.

Niedzwiecki

Rizzieri

Bartlett

N.L.

(2008) Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 140: 313–319.

122.

Spencer

Prince

H.M.

Roberts

A.W.

Prosser

I.W.

Bradstock

K.F.

Coyle

(2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27: 1788–1793.

123.

Szilagyi

Ghali

M.P.

(2006) Pharmacological therapy of vascular malformations of the gastrointestinal tract. Can J Gastroenterol 20: 171–178.

124.

Teo

S.K.

Colburn

W.A.

Tracewell

W.G.

Kook

K.A.

Stirling

D.I.

Jaworsky

M.S.

(2004) Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 43: 311–327.

125.

Thomas

D.A.

Giles

F.J.

Albitar

Cortes

J.E.

Verstovsek

Faderl

(2006) Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106: 1974–1984.

126.

Toffalini

Demoulin

J.B.

(2010) New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 116: 2429–2437.

127.

Treon

S.P.

Soumerai

J.D.

Branagan

A.R.

Hunter

Z.R.

Patterson

C.J.

Ioakimidis

(2008) Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 112: 4452–4457.

128.

Vacca

Scavelli

Montefusco

Di Pietro

Neri

Mattioli

(2005) Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23: 5334–5346.

129.

van Marion

A.M.

Auwerda

J.J.

Minnema

M.C.

van Oosterom

Adelmeijer

de Groot

P.G.

(2005) Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 94: 1341–1343.

130.

van Rhee

Dhodapkar

Shaughnessy

J.D.

Jr Anaissie

Siegel

Hoering

(2008) First thalidomide clinical trial in multiple myeloma: a decade. Blood 112: 1035–1038.

131.

Vasiliauskas

E.A.

Kam

L.Y.

Abreu-Martin

M.T.

Hassard

P.V.

Papadakis

K.A.

Yang

(1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117: 1278–1287.

132.

Vogelsang

G.B.

Farmer

E.R.

Hess

A.D.

Altamonte

Beschorner

W.E.

Jabs

D.A.

(1992) Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326: 1055–1058.

133.

von Lilienfeld-Toal

Hahn-Ast

Furkert

Hoffmann

Naumann

Bargou

(2008) A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 81: 247–252.

134.

von Moos

Stolz

Cerny

Gillessen

(2003) Thalidomide: from tragedy to promise. Swiss Med Wkly 133: 77–87.

135.

Waage

Gimsing

Fayers

Abildgaard

Ahlberg

Bjorkstrand

(2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116: 1405–1412.

136.

Weber

Rankin

Gavino

Delasalle

Alexanian

(2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16–19.

137.

Weber

D.M.

Chen

Niesvizky

Wang

Belch

Stadtmauer

E.A.

(2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133–2142.

138.

Wei

J.C.

Chan

T.W.

Lin

H.S.

Huang

Chou

C.T.

(2003) Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 30: 2627–2631.

139.

Wijermans

Schaafsma

Termorshuizen

Ammerlaan

Wittebol

Sinnige

(2010) Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 28: 3160–3166.

140.

Wnendt

Finkam

Winter

Ossig

Raabe

Zwingenberger

(1996) Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues. Chirality 8: 390–396.

141.

Zangari

Anaissie

Barlogie

Badros

Desikan

Gopal

A.V.

(2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98: 1614–1615.

142.

Zangari

Fink

L.M.

Elice

Zhan

Adcock

D.M.

Tricot

G.J.

(2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27: 4865–4873.

143.

Zangari

Saghafifar

Anaissie

Badros

Desikan

Fassas

(2002a) Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13: 187–192.

144.

Zangari

Siegel

Barlogie

Anaissie

Saghafifar

Fassas

(2002b) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100: 1168–1171.

145.

Zeldis

J.B.

Williams

B.A.

Thomas

S.D.

Elsayed

M.E.

(1999) S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21: 319–330.